Late Means Late The presented data has been just released to Anavex and processed to be delivered just in nick of time to Dr. Farlane to be presented at CTAD 2022. Unfortunately, I had not saved the presentation slides as I initially downloaded them and they have been remoed now. If anybody has a copy … Continue reading Anavex Life Sciences Phase2a For Alzheimer’s Vindicated with 509 Sample Size Phase2b/3. Blarcamesine $AVXL
Refined Illustration For Possible Performance of Blarcamesine On The Background of Donezepil, Simufilam and Donezepil Placebo, All Imperfect Comparison First thing is to point to a mistaken plus sign of the Avg. Delta ADAS-COG11, which should be -7.21, not 7.21. Green Line represents the performance of Donezepil Placebo from Donezepil Label Fig.2. But this is … Continue reading Final Prognostication Before December 1, 2022 CTAD San Francisco Presentation.
It was suggested to me to comparing the hypothetical performance of Blarcamesine in phase 2b/3 to Donezepil. Hat Tip to @Trainguy1. I tried to compare the 3 drugs, including 9 months performnace of Simufilam, to Donezepil as it was formated or presented in Fig. 2 on Donezepil Label coming with the drug, and FDA approved. … Continue reading Donezepil, Simufilam And Blarcamesine Performance Compared As Much As It Is Possible. $SAVA $AVXL
Plotting Δ ΜΜSE or Δ ADAS-Cog11 or Just Changes in Cognition for Each Patient I came with an idea to plot in a given trial all the cognition changes from the highest score to the lowest. On a spreadsheet I arranged patients in this order with their corressponding cognition deltas scores. When you see a … Continue reading In Search of Therapeutic Effect Patterns In Simufilam, Blarcamesine and Approximation of Placebo. $SAVA $AVXL
This is quick and dirty, I have no time for bibliography and references. I had been giving references links but now I have no time so if you want references I can provided them on request. For most of you the references for those illustrations are already known. I apologize for misspellings and gramatical errors. … Continue reading Comparing Apples To Oranges, Or Rather The Hypotetical Performance Of Blarcamesine And Simufilam. $AVXL vs. $SAVA
You can devine the future from coffee grinds as well as from the language change... But only if you don't know much about the implications of language in phase 2b/3 for Blarcamesine for Alzheimer's. Mr. Brodkin has published this tweet. Link: https://twitter.com/jesse_brodkin/status/1550477966123171840?s=20&t=MdTQ5Aes7PJyFbCFHRQQAQ One of the points he makes is that Anavex has changed the wording … Continue reading Change Of Language On ClinicalTrials.Gov Page For Blarcamesine Phase 2b/3 Alzheimer’s Trial. $AVXL
All Medicines Are Poisons (in large enough doses)! I hope that things would be so simple as just calculating IC50 and blood concentration and then passing a judgement on the therapeutic effect of the drug. Things happen in time, there is the liver, Brain Blood Barrier, intestines, stomach juices all contributing to the level of … Continue reading Mr. Brodkin And Four Arithmetic Operation But No Calculus. All About $AVXL. Part Two.
There will be number of posts on this lengthy twitter post by Jesse Brodkin, who claims to be a scientist and enterpreneur. let's see the first assertion made by Mr. Brodkin. Mr. Brodkin claimes that Anavex2-73 is being dosed 30 to 100 fold too low to engage SIGMAR1 or M-1 receptors. So let's run the … Continue reading Mr. Brodkin And His Post On Twitter About $AVXL. Part One.
This blogpost is for purposes of education only. Disclaimer. I am an owner of a modest 1,700 square feet house. My annual electric bill for about 5,200 kWh. Why did I decided to purchase a solar panel system for my house considering relatively small electricity usage? It is a rather longer story than it seems. … Continue reading Solar Panels Or Locking In The Cost Of Electricity. Energy Arbitrage In Time.
Another Paper Supports Anavex's SIGMAR1 Platform Just a day before Anavex published release with reference to a paper looking into Alzheimer's patients brain geograghy of mitochodrial dysfunction, synaptic density, oxidative stress and their impact on brain volume. All this was done in vivo that is on living AD patients as novel radiograghic markers to measure … Continue reading SIGMAR1 As Cell Stress Indicator In Alzheimer’s Points To Great Results In Phase 2b/3 For Blarcamesine. $AVXL